|
AU4016099A
|
|
Use of cell surface receptor targeted molecules for the treatment of viral diseases
|
|
AU6087396A
|
|
Use of cell surface receptor targeted molecules for the treatment of viral diseases
|
|
US6022950A
|
|
Hybrid molecules having translocation region and cell-binding region
|
|
US5668255A
|
|
Hybrid molecules having translocation region and cell-binding region
|
|
AU3658093A
|
|
Desensitization to specific allergens
|
|
AU2261392A
|
|
Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis
|
|
EP0584251A1
|
|
Cytokine receptor targeted molecules for treatment of meoplastic cell growth.
|
|
AU1992792A
|
|
Interleukin receptor targeted molecules for treatment of inflammatory arthritis
|
|
AU1643692A
|
|
Use of cell surface receptor targeted molecules for the treatment of viral diseases
|
|
US5571507A
|
|
Methods of treating diabetes
|
|
AU8947391A
|
|
Mammalian model of a malignant disorder
|
|
WO9206117A1
|
|
Inhibiting unwanted immune responses
|
|
EP0511302A1
|
|
Cytotoxic cell-specific protease-related molecules and methods
|
|
CA2071969A1
|
|
Hybrid molecules having translocation region and cell-binding region
|
|
NZ234674A
|
|
Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates
|
|
CA2063799A1
|
|
Prevention of internal initiation
|
|
EP0433442A1
|
|
Hybrid molecules
|
|
US5110912A
|
|
Purification of il-2-containing hybrid compounds
|
|
WO9010015A1
|
|
Chimeric toxin
|
|
WO8805471A1
|
|
Cytotoxic lymphocyte-specific protease-related molecules and methods
|
